港股異動丨創科實業(0669.HK)漲約4% 同業對手季報出色 高盛其表現更佳
格隆匯7月28日丨創科實業(0669.HK)漲約4%,報135.6港元,總市值2486億港元。高盛發研報指,7月27日,該行參加了創科實業主要競爭對手SWK(美國史丹利公司)今年次季業績網絡直播會議。通過對比,該行可以觀測到創科實業的實際經營情況。研報續指,SWK2021年二季度自然增長率達33%。鑑於同業表現,該行認為創科實業可能會比行業趨勢提供更好的業績。該行將其今年下半年收入增長預測從同比增長5%上調至同比增長15%,並將2021年全年收入增長預測從同比增長19%上調至同比增長25%,將目標價由137港元提升至149港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.